Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) traded up 8.6% on Wednesday . The stock traded as high as $45.09 and last traded at $44.97. 711,930 shares traded hands during mid-day trading, a decline of 5% from the average session volume of 751,268 shares. The stock had previously closed at $41.40. Wall […]
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) traded up 8.6% on Wednesday . The stock traded as high as $45.09 and last traded at $44.97. 711,930 shares traded hands during mid-day trading, a decline of 5% from the average session volume of 751,268 shares. The stock had previously closed at $41.40. Wall […]
Avidity Partners Management LP grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 55.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 844,500 shares of the biopharmaceutical company’s stock after acquiring an additional 300,500 shares during the period. […]
Avidity Partners Management LP grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 55.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 844,500 shares of the biopharmaceutical company’s stock after acquiring an additional 300,500 shares during the period. […]
Seven Eight Capital LP increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 140.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,906 shares of the biopharmaceutical company’s stock after purchasing an additional 26,831 shares during the […]